Kura Oncology 2Q FY26 net loss widens to $68.3 million; revenue rises to $20.87 million - KURA News | RalliesKura Oncology 2Q FY26 net loss widens to $68.3 million; revenue rises to $20.87 million
K
KURA• Quarterly results and revenue
- Kura Oncology posted a 2Q 2026 net loss of $68.33 million, or $0.77 a share, versus a $66.12 million loss.
- Total revenue rose to $20.87 million, driven by $9.1 million in net product revenue from KOMZIFTI’s launch.
- SG&A expenses climbed to $31.75 million from $25.17 million, while R&D spending edged down to $61.89 million.
KOMZIFTI launch metrics and cash position
- KOMZIFTI net product revenue rose 57% from 1Q to $9.1 million; new patient starts increased 35% to about 115.
- Cash, cash equivalents and short-term investments were $519.03 million; management expects runway through a pivotal KOMET-017 readout in 2028.
BLSM
•
